NEW YORK, June 16, 2016 /PRNewswire/ --
On Wednesday, June 15, 2016, the
NASDAQ Composite ended the trading session at 4,834.93, down 0.18%;
the Dow Jones Industrial Average edged 0.20% lower to finish at
17,640.17; and the S&P 500 closed at 2,071.50, down 0.18%.
However, six out of nine sectors ended the session in positive.
Stock-Callers.com has initiated coverage on the following equities:
Array BioPharma Inc. (NASDAQ: ARRY), PDL BioPharma Inc. (NASDAQ:
PDLI), Advaxis Inc. (NASDAQ: ADXS), and TetraLogic Pharmaceuticals
Corporation (NASDAQ: TLOG). Learn more about these stocks by
accessing their free trade alerts at:
http://stock-callers.com/
Boulder, Colorado headquartered
biopharma Company, Array BioPharma Inc.'s stock lost 1.22% to close
the day at $3.25 with a total volume
of 1.73 million shares traded. The Company's shares have gained
9.06% in the last one month and 25.00% in the previous three
months. The stock is trading 0.27% above its 50-day moving average.
Additionally, Array BioPharma's stock has a Relative Strength Index
(RSI) of 42.96. Sign up and read the free notes on ARRY at:
http://stock-callers.com/
On Wednesday, shares in PDL BioPharma Inc. which manages a
portfolio of patents and royalty assets in the U.S. and
Europe, ended the session 0.64%
higher at $3.15 with a total volume
of 954,362 shares traded. Shares of the Company traded at a PE
ratio of 1.70. The Company's shares have advanced 2.44% in the last
one month and 9.08% in the previous three months. The stock is
trading 6.14% below its 50-day moving average. Moreover, shares of
PDL BioPharma have an RSI of 43.41. The complimentary notes on PDLI
can be downloaded in PDF format at:
http://stock-callers.com/
Princeton, New Jersey-based
clinical stage biotech Company, Advaxis Inc.'s stock finished
Wednesday's session 2.50% higher at $8.20 with a total volume of 569,040 shares
traded. The Company's shares have gained 16.98% in the last one
month. The stock is trading below its 50-day moving average by
4.72%. Advaxis' stock has an RSI of 43.68. Register for free on
Stock-Callers.com and access the latest research on ADXS at:
http://stock-callers.com/
On Wednesday, shares in Malvern,
Pennsylvania headquartered clinical-stage biopharma Company,
TetraLogic Pharmaceuticals Corp., ended the day 4.15% lower at
$0.28 with a total volume of 241,043
shares traded. The Company's shares have surged 34.20% in the last
one month and 44.79% in the previous three months. The stock is
trading above its 50-day moving average by 1.80%. Furthermore,
shares of TetraLogic Pharmaceuticals have an RSI of 46.59. Get free
access to your trade alert on TLOG at:
http://stock-callers.com/
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly
at:
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
Email: info@stock-callers.com
Phone number: +44 330 808 3765
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA
